Sign up United Kingdom
ImmuPharma PLC (LON:IMM)

ImmuPharma PLC (LON:IMM)


Share Price
18.35 p
Change
5.525 (43.08 %)
Market Cap
£25.59 m
Proactive Investors - Run By Investors For Investors

ImmuPharma PLC RNS Release

Appointment of Joint Brokers


RNS Number : 1740B
Immupharma PLC
19 September 2018
 

 

19 September 2018

 

 

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Appointment of Joint Brokers

 

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company's NOMAD and broker.

 

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma said:

 

"As per our recently announced corporate update, we are looking forward with confidence to the future progress of ImmuPharma. As part of our continued proactive investor relations strategy, we also look forward to working with Stanford Capital and SI Capital as part of our corporate advisory team."

 

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496

 

Northland Capital Partners Limited (NOMAD & Joint Broker)
David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance
Rob Rees, Corporate Broking

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman

 

SI Capital (Joint Broker)                                                                     

Nick Emerson

 

+44 (0)20 3861 6625

 

 

 

 

+44 (0) 20 3815 8880

 

 

+44 (0) 1483 413500









 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPFKFDDABKDQCD

ImmuPharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use